Formulations and methods for vascular permeability-related diseases or conditions
Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.
1. A method to decrease vascular permeability in a subject in need thereof, comprising administering a therapeutic agent to the subject at a dose of no greater than an amount equivalent to 2 mg/kg of rapamycin,
wherein the subject in need thereof has a disease or condition selected from the group consisting of retinal edema, neuroretinitis, vasculitis, toxic metabolic brain edema, hemangiomas, von Hippel Lindau disease, angioneurotic edema, snake bite, high altitude cerebral edema (HACE), high altitude pulmonary edema (HAPE), pulmonary edema associated with smoke inhalation, pulmonary edema associated with anoxia, hyponatremic brain edema, edema associated with blunt trauma, brain edema following stroke or closed head injury, and corneal edema,
and the therapeutic agent is rapamycin or a pharmaceutically acceptable salt or ester thereof.
2. The method of claim 1 , wherein the therapeutic agent is rapamycin, and the subject is a human subject.
3. The method of claim 1 , wherein the therapeutic agent is rapamycin, and the subject in need thereof has a disease or condition is selected from the group consisting of retinal edema, von Hippel Lindau disease, and corneal edema.
4. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.5 mg/kg of rapamycin.
5. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.27 mg/kg of rapamycin.
6. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.07 mg/kg of rapamycin.
7. The method of claim 1 , wherein the therapeutic agent is administered to the subject in need thereof at a dose of no greater than an amount equivalent to 0.014 mg/kg of rapamycin.
8. The method of any of claims 4 - 7 , wherein the therapeutic agent is rapamycin and the subject is a human subject.
9. The method of claim 1 , wherein the therapeutic agent is rapamycin, and the rapamycin is administered in a formulation containing about 2% w/w rapamycin, about 4% w/w ethanol, and about 94% w/w PEG 400.